Drug transporters in breast cancer: response to anthracyclines and taxanes

References

• HUGO gene nomenclature committee. Available from: www.genenames.org/genefamilies/ABC
   Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9(1):105-27
   PubMed Web of Science ®Google Scholar
• Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009;10(3):218-27
   PubMed Web of Science ®Google Scholar
• World health organization. Available from: www.who.int/cancer/detection/breastcancer/en/index1.html
   Google Scholar
• Dieci MV, Arnedos M, Delaloge S, Andre F. Quantification of residual risk of relapse in breast cancer patients optimally treated. Breast 2013;22(2):S92-5
   Google Scholar
• Kumler I, Brunner N, Stenvang J, et al. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res Treat 2013;138(2):347-58
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2(1):86-98
   PubMedGoogle Scholar
• Sharom FJ. Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol 2014;4:41
   PubMedGoogle Scholar
• Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med 2014;7:53-64
   PubMedGoogle Scholar
• Kathawala RJ, Gupta P, Ashby CRJr, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 2015;18:1-17
   PubMed Web of Science ®Google Scholar
• Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 2006;95(12):2767-77
   PubMed Web of Science ®Google Scholar
• Green H, Soderkvist P, Rosenberg P, et al. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12(3 Pt 1):854-9
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010;102(6):1003-9
   PubMed Web of Science ®Google Scholar
• Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003;22(5):1117-21
   PubMed Web of Science ®Google Scholar
• Ashariati A. Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med Indones 2008;40(4):187-91
   PubMedGoogle Scholar
• Wu H, Kang H, Liu Y, et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol 2012;138(9):1449-62
   PubMed Web of Science ®Google Scholar
• Ji M, Tang J, Zhao J, et al. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther 2012;13(5):264-71
   PubMed Web of Science ®Google Scholar
• Cizmarikova M, Wagnerova M, Schonova L, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010;10(1):62-9
   PubMed Web of Science ®Google Scholar
• George J, Dharanipragada K, Krishnamachari S, et al. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 2009;9(3):161-5
   PubMed Web of Science ®Google Scholar
• Rodrigues FF, Santos RE, Melo MB, et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 2008;7(1):177-83
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Tulsyan S, Agarwal G, et al. Influence of ABCB1 genetic variants in breast cancer treatment outcomes. Cancer Epidemiol 2013;37(5):754-61
   PubMed Web of Science ®Google Scholar
• Green H, Stal O, Bachmeier K, et al. Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett 2011;313(2):145-53
   PubMed Web of Science ®Google Scholar
• Afsar NA, Haenisch S, Mateen A, et al. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol 2010;107(1):570-6
   PubMed Web of Science ®Google Scholar
• Ferrero JM, Etienne MC, Formento JL, et al. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer 2000;82(1):171-7
   PubMed Web of Science ®Google Scholar
• Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001;92(4):452-8
   PubMedGoogle Scholar
• Atalay C, Demirkazik A, Gunduz U. Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer. J Chemother 2008;20(6):734-9
   PubMed Web of Science ®Google Scholar
• Taheri M, Mahjoubi F. MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients. Dis Markers 2013;34(6):387-93
   PubMed Web of Science ®Google Scholar
• Singh LC, Chakraborty A, Mishra AK, et al. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women. Med Oncol 2012;29(2):539-46
   PubMed Web of Science ®Google Scholar
• Lizard-Nacol S, Genne P, Coudert B, et al. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 1999;19(4C):3575-81
   PubMed Web of Science ®Google Scholar
• Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9(2):827-36
   PubMed Web of Science ®Google Scholar
• He L, Hao C, Lin B, et al. P-glycoprotein expression in primary breast cancer. Chin Med Sci J 1995;10(1):12-15
   PubMedGoogle Scholar
• Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002;8(4):1068-74
   PubMed Web of Science ®Google Scholar
• Ro J, Sahin A, Ro JY, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990;21(8):787-91
   PubMed Web of Science ®Google Scholar
• Chung HC, Rha SY, Kim JH, et al. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 1997;42(1):65-72
   PubMed Web of Science ®Google Scholar
• Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77(4):621-6
   PubMed Web of Science ®Google Scholar
• Kim B, Fatayer H, Hanby AM, et al. Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS ONE 2013;8(5):e62766
   Google Scholar
• Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 1995;36(1):61-9
   PubMed Web of Science ®Google Scholar
• Linn SC, Pinedo HM, van Ark-Otte J, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997;71(5):787-95
   PubMed Web of Science ®Google Scholar
• Kovalev AA, Tsvetaeva DA, Grudinskaja TV. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol 2013;35(4):287-90
   PubMedGoogle Scholar
• Fajac A, Gligorov J, Rezai K, et al. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 2010;103(4):560-6
   PubMed Web of Science ®Google Scholar
• Hertz DL, Motsinger-Reif AA, Drobish A, et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012;134(1):401-10
   PubMed Web of Science ®Google Scholar
• Levy P, Gligorov J, Antoine M, et al. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2013;139(2):421-8
   PubMed Web of Science ®Google Scholar
• Tulsyan S, Chaturvedi P, Singh AK, et al. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene 2014;543(1):69-75
   PubMed Web of Science ®Google Scholar
• Kim HJ, Im SA, Keam B, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 2015;106(1):86-93
   PubMed Web of Science ®Google Scholar
• Chang H, Rha SY, Jeung HC, et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009;20(2):272-7
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim JH, Im SA, et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 2012;83(4):218-27
   PubMed Web of Science ®Google Scholar
• Yang X, Uziely B, Groshen S, et al. MDR1 gene expression in primary and advanced breast cancer. Lab Invest 1999;79(3):271-80
   PubMed Web of Science ®Google Scholar
• Fujita T, Ito K, Izumi H, et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 2005;11(24 Pt 1):8837-44
   PubMed Web of Science ®Google Scholar
• Horak CE, Pusztai L, Xing G, et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res 2013;19(6):1587-95
   PubMed Web of Science ®Google Scholar
• Rincon M, Broadwater G, Harris L, et al. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 2006;100(3):301-8
   PubMed Web of Science ®Google Scholar
• Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003;46(23):4805-17
   PubMed Web of Science ®Google Scholar
• Ries F, Dicato M. Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. Med Oncol Tumor Pharmacother 1991;8(1):39-43
   PubMedGoogle Scholar
• Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12(9):1771-7
   PubMed Web of Science ®Google Scholar
• Bates SE, Meadows B, Goldspiel BR, et al. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemother Pharmacol 1995;35(6):457-63
   PubMed Web of Science ®Google Scholar
• Warner E, Hedley D, Andrulis I, et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 1998;4(6):1451-7
   PubMed Web of Science ®Google Scholar
• Lehnert M, Mross K, Schueller J, et al. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer 1998;77(7):1155-63
   PubMed Web of Science ®Google Scholar
• Belpomme D, Gauthier S, Pujade-Lauraine E, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000;11(11):1471-6
   PubMed Web of Science ®Google Scholar
• Saeki T, Tsuruo T, Sato W, Nishikawsa K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol 2005;56(1):84-9
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Cowan KH, Solomon D, et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996;14(4):1173-84
   PubMed Web of Science ®Google Scholar
• Toppmeyer D, Seidman AD, Pollak M, et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002;8(3):670-8
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104(4):682-91
   PubMed Web of Science ®Google Scholar
• Carlson RW, O’Neill AM, Goldstein LJ, et al. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 2006;24(7):677-81
   PubMed Web of Science ®Google Scholar
• Helgason HH, Kruijtzer CM, Huitema AD, et al. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer 2006;95(7):794-800
   PubMed Web of Science ®Google Scholar
• Helgason HH, Koolen SL, Werkhoven E, et al. Phase II and pharmacological study of oral docetaxel plus cyclosporin a in anthracycline pre-treated metastatic breast cancer. Curr Clin Pharmacol 2014;9(2):139-47
   PubMedGoogle Scholar
• Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 2014;10(10):1337-54
   PubMed Web of Science ®Google Scholar
• Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101(21):1446-52
   PubMed Web of Science ®Google Scholar
• Itoh K, Sasaki Y, Fujii H, et al. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Clin Cancer Res 2000;6(10):4082-90
   PubMed Web of Science ®Google Scholar
• Hu XF, Slater A, Rischin D, et al. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer 1999;79(5-6):831-7
   PubMed Web of Science ®Google Scholar
• Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996;27(2):251-5
   PubMedGoogle Scholar
• Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993(15):55-61
   PubMedGoogle Scholar
• Kelly RJ, Robey RW, Chen CC, et al. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 2012;17(4):512
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17(3):569-80
   PubMed Web of Science ®Google Scholar
• Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006;23(7):1574-85
   PubMed Web of Science ®Google Scholar
• Prasad P, Cheng J, Shuhendler A, et al. A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv Transl Res 2012;2(2):95-105
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55(1):3-29
   PubMed Web of Science ®Google Scholar
• Tamaki A, Ierano C, Szakacs G, et al. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011;50(1):209-32
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Sargent DJ. Design of clinical trials for biomarker research in oncology. Clin Investig (Lond) 2011;1(12):1629-36
   Google Scholar